Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Todos Share Update - 11/09/23
75M shares issued since update on 9/29/23.
https://www.otcmarkets.com/stock/TOMDF/security
Novavax Form 10-Q Filing
November 9, 2023
10-Q Filing PDF
.
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
https://ir.novavax.com/press-releases/2023-11-09-Novavax-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Highlights
Also, don't cozy up to any CEO in private conversations thinking you somehow have an edge over other investors. And kissing his ass on conference calls with 12 CONGRATULATIONS makes you look like a noob investor to everyone else. No one will come to your rescue when you try to convince others to load up on the shares after a "Come to Jesus" chat with the CEO.
GDS is real. No cure except death. To help in the afterlife, perhaps someone can slip a collection of photos of GC in the coffin before burial.
What do you expect from someone who posts endlessly as an authority on the Covid-19 virus and treatments but doesn't even possess a rudimentary understanding of the difference between viral and bacterial infections, as demonstrated in this infamous and hilarious post. 😂
I see the phone connection for the dial-up modem. Where's the phone he used for his Come To Jesus talk with the AMBS CEO, and for follow-up calls to AMBS investors notifying them the WHALES are coming, and his advice to hit the ask, even if it continues to move higher.
I think most who followed his frequent changes in AMBS sentiment and who shared a high level of skepticism about this clown saw this as a lame attempt to unload his AMBS shares as they were hitting the ask and driving the price higher. I'm told no one took he bait and he was later very upset about it. Did these WHALES ever show up?
Thanks for your input. I got the Novavax vaccine today at Costco, along with the flu vaccine. Still taking Tollovid daily. Never had Covid.
Don't take the fake analyst off ignore. Life is so much better without the rants of that nut in your life. I guess those 9 specialists can't cure the Gerald Derangement Syndrome.
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
https://ir.novavax.com/press-releases/2023-10-31-Novavaxs-Updated-Nuvaxovid-TM-COVID-19-Vaccine-Receives-Positive-CHMP-Opinion-in-the-EU
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
https://ir.novavax.com/press-releases/2023-10-31-Novavaxs-Updated-COVID-19-Vaccine-Now-Approved-in-the-EU
I wonder if the authorized shares will remain unchanged like during the last reverse split. Wouldn't that be something?
It's just one of the discount codes Todos automatically applies to purchases when there's a sale. It looks like a 10% discount for 2 bottles of Tollovid ordered.
Picked up more NVAX shares today at near the low of the day. I'll keep adding at these prices.
BUY BUY BUY!!!
Buy all you can. When you mention to friends you bought at below 0.30, be sure to ignore the RS and tell the the current after-RS price to impress them and solidify your position as an investment GURU. LMAO
You called this RS many months ago. Spot on.
Where's the fake analyst when you need some commentary on this fantastic investment?
Todos Share Update - 10/20/23
No shares issued since update on 9/29/23.
https://www.otcmarkets.com/stock/TOMDF/security
This is all everything anyone needs to know. Catastrophic losses. Financial insolvency. Six-figure losses.
https://www.reddit.com/r/TOMDF/comments/sggcka/jpetroinc_warning_avoid_this_deceptive_manipulator/
Novavax Statement on 2023-2024 COVID-19 Vaccination Season
October 16, 2023
https://ir.novavax.com/press-releases/Novavax-Statement-on-2023-2024-COVID-19-Vaccination-Season
Todos Share Update - 10/13/23
No shares issued since update on 9/29/23.
https://www.otcmarkets.com/stock/TOMDF/security
There was no reply at the time I made the post. I'll keep checking and post if that changes. From what GC has stated about the crowdfunding, he already has an investor to fund the trials. The crowdfunding allows other investors to participate. We should be getting news soon.
CEO on X - 10/7 and 10/8/23
Link to image: https://pbs.twimg.com/media/F72c8CnXQAA6jSY?format=jpg&name=large
Science: Should you pick Novavax’s COVID-19 shot over mRNA options?
Limited data and lack of head-to-head studies make comparisons tricky
October 6, 2023
For cardiologist Eric Topol, this week’s vaccine news presented a personal dilemma. Topol, who directs the Scripps Research Translational Institute and is a popular commenter on COVID-19 research, had hoped to get an updated COVID-19 vaccine from Novavax, rather than a messenger RNA (mRNA) shot from Pfizer or Moderna. Novavax relies on an older, protein-based approach that has shown long-lasting effects against other pathogens, and Topol wondered whether it might produce more durable protection. On Tuesday, it seemed he might get his chance: a drugstore he visited for an mRNA vaccine ran out of doses, and hours later the U.S. Food and Drug Administration authorized a Novavax shot well-matched to current COVID-19 variants. The green light marks the first time Novavax will be widely available to teens and adults.
“It’s hard to know how it compares” to mRNA vaccines, Topol admits; there are no head-to-head studies to rely on. In clinical trials, Novavax appeared less likely than mRNA shots to cause side effects like headache and fatigue. But how does it stack up against mRNA vaccines when it comes to protection against SARS-CoV-2? The question has been vexingly difficult to answer.
Some hints are emerging, including the first large study of Novavax in the real world, published this week by a team in Italy. The results are far from definitive, but they suggest “there aren’t massive differences” between the vaccines, says Alberto Mateo Urdiales, an epidemiology and infectious disease researcher at the Italian National Institute of Health, who led the study.
Whereas mRNA vaccines carry instructions for making a SARS-CoV-2 protein, Novavax directly delivers a fragment of that viral spike protein with an adjuvant for boosting immune response. Such protein subunit vaccines have yielded durable protection against various pathogens including hepatitis B and shingles, along with some respiratory ailments such as pneumonia. A version of the Novavax vaccine targeting the original SARS-CoV-2 variant was approved as a primary vaccination series and first booster in the United States in 2022; it also became available in Europe that year. Its tried-and-true technology appealed to some people wary of the new mRNA approach. And unlike the more fragile mRNA shots, it lasts for months in the refrigerator. But uptake has been low and the company is banking on more shots in arms this fall.
The Italian team tried to pin down how well the shot actually works, analyzing data on more than 20,000 Italians who had received two doses as their primary vaccine series in 2022. After 4 months, the vaccine was 55% effective at staving off symptoms from a SARS-CoV-2 infection and 28% effective at preventing infection altogether, the researchers reported in JAMA Network Open. That’s roughly comparable to how the mRNA vaccines have performed, Mateo Urdiales says. He cautions that the emergence of SARS-CoV-2 variants, repeated boosting, and swelling numbers of infections make it hard to compare numbers across the studies of effectiveness conducted to date.
Smaller studies, meanwhile, have tried to address another reason a Novavax booster appeals to people like Topol: the possibility that “mixing and matching” various COVID-19 vaccines might provide better protection than any single vaccine brand. “There was theoretical hope that since these vaccines work in slightly different ways, they would have different strengths in terms of which part of the immune system they activate best,” says Angela Branche, an infectious disease specialist at the University of Rochester. She co-chairs a mix-and-match study called COVAIL that includes another protein subunit vaccine from the company Sanofi, which is not available in the U.S.
At the University of Maryland School of Medicine, infectious disease specialist and vaccine researcher Kirsten Lyke is leading a mix-and-match study in which 67 of the roughly 830 participants got the original Novavax vaccine as a first booster, having received Pfizer, Moderna, or Johnson & Johnson as their primary vaccination. Three months after that booster, their levels of neutralizing antibodies were similar to those in people who got an mRNA booster instead, the team reported in July in NPJ Vaccines. (Neutralizing antibodies may help protect against infection and illness.)
Mixing and matching has sometimes produced superior immune responses, both for COVID-19 and other vaccines. But Branche notes that protein and mRNA vaccines may be more similar, immunologically, than they appear at first blush, because both rely on the same SARS-CoV-2 spike protein to trigger an immune response.
Researchers also want to know how long protection lasts with Novavax versus mRNA vaccines. Mateo Urdiales found that protection from infection dropped in the first 4 months after Novavax vaccination, but it seemed to hold steady against symptoms; other studies have shown that with mRNA vaccines, protection against symptoms also declines in that time frame.
Lyke’s analysis hinted that levels of neutralizing antibodies waned more slowly after a Novavax booster than after an mRNA booster. But that doesn’t prove Novavax’s protection is more durable, she stresses: Novavax hit the scene much later, when many recipients had enhanced immunity from a previous infection. “This durability question is influenced by many different factors other than what the vaccine does,” Branche notes.
Ultimately, “I’m not sure that on their face any of the vaccines are particularly better than the other,” Lyke says.
Comparisons of safety are uncertain, too. A key concern for mRNA vaccines is myocarditis, an inflammation of the heart, which occurs, rarely, after vaccination, especially in young men. In Novavax trials, there were four cases of myocarditis in the vaccine arm within 20 days of vaccination and none in the placebo group during that time frame. June data from the Australian government noted myocarditis reports for three to four of every 100,000 Novavax doses, a rate roughly similar to what Australia reports for the mRNA vaccines.
But because the side effect is so uncommon and Novavax has been much less widely used, “I don’t think anyone can know the true rate yet of myocarditis from Novavax,” says Walid Gellad, a physician who studies drug safety at the University of Pittsburgh. “I would not assume yet that Novavax is the solution to the myocarditis issue of mRNA” vaccines, he adds.
Scientists hope more data on Novavax will come. Lyke is examining immune responses 6 months and 12 months after the original Novavax booster in her small cohort. Meanwhile, a rare head-to-head clinical trial began in February in Melbourne, Australia. It includes almost 500 people who already received three vaccine doses. Some are being randomized to get either a Moderna bivalent booster, which became available last fall, or the original Novavax vaccine. Others who opted against any booster will serve as a control group. “We want to determine the best vaccine for ongoing boosters,” says Claire von Mollendorf, who co-leads the study at the Murdoch Children’s Research Institute. Von Mollendorf expects initial results from a month after vaccination to be published around the end of the year. Results from a 12-month follow-up won’t come until early 2025.
The best time to pit Novavax head-to-head against the other COVID-19 vaccines may be right now, with updated boosters becoming available that all target the same version of Omicron, called XBB. This fall, “I think most people will take what they are offered, and then you can compare,” Mateo Urdiales says. He’s hoping to launch such a study, using the Italian registry data on vaccination.
As for Topol, upcoming travel and uncertainty about Novavax’s availability led him to opt against waiting. He got a Pfizer shot at a nearby grocery store this week—though he still wonders whether and how a dose of Novavax might have been different.
Source: https://www.science.org/content/article/should-you-pick-novavax-s-covid-19-shot-over-mrna-options
CNBC: Novavax’s updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
October 7, 2023
KEY POINTS
• Novavax’s updated Covid vaccine is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans — but analysts aren’t worried about that delay.
• It still appears well positioned to compete with the other companies in the U.S. Covid vaccine market this fall, particularly after logistical issues hampered the rollout of the other shots.
• That’s good news for Novavax, which is working to strengthen its financial position after raising doubts about its ability to stay in business at the beginning of the year.
Americans can finally get their hands on Novavax’s newest Covid vaccine after U.S. regulators greenlighted the shot this week.
The vaccine’s arrival comes nearly three weeks after new jabs from Pfizer and Moderna reached the public, and after more than 4 million patients rolled up their sleeves to get a shot in September. But Wall Street analysts aren’t worried about that delay.
They said Novavax appears well positioned to catch up and compete this fall with the other companies in the U.S. Covid vaccine market, particularly after logistical issues hampered the rollout of the other shots and a Food and Drug Administration label that allows for wide accessibility to Novavax’s jab, among other factors.
“I’m really not concerned about the timeline or lag relative to the other shots,” B. Riley Securities analyst Mayank Mamtani told CNBC. He added that regulators cleared Novavax’s new shot only slightly later than what the company had estimated, which was late in the third quarter.
That’s good news for Novavax, which is working to strengthen its financial position after raising doubts about its ability to stay in business at the beginning of the year. The biotech company is banking on sales of its updated Covid vaccine — its only commercially available product — and a broad cost-cutting push to help it stay afloat.
Public health officials see Novavax’s vaccine as a valuable alternative for people who don’t want to take messenger RNA shots from Pfizer and Moderna, which teach cells how to make proteins that trigger an immune response against Covid. Novavax’s shot fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles.
Silvia Taylor, Novavax’s chief corporate affairs and advocacy officer, told CNBC that the company has collected data showing that 25% to 30% of people prefer a protein-based vaccine.
“We look forward to meeting this demand and more in the wake of new variants and rising COVID cases,” Taylor said in a statement.
Shares of Novavax jumped more than 10% on Tuesday after the FDA cleared its new shot. But the company’s stock is still down more than 25% year to date after shedding more than 90% of its value last year.
Novavax’s shot has a broad authorization label
The FDA authorized Novavax’s updated vaccine — which targets the omicron subvariant XBB.1.5 — for emergency use in people ages 12 and older. Patients previously vaccinated with an older Covid vaccine are eligible to receive one dose of Novavax’s new jab, while unvaccinated people can receive two doses, according to the authorization.
The FDA similarly approved the new shots from Pfizer and Moderna for people ages 12 and older, but the agency also authorized those vaccines for emergency use in children ages 6 months through 11 years old.
Still, Mamtani said the authorization label for Novavax’s new vaccine is “broad and without any notable restrictions for the first time,” which will likely make the shot as widely accessible to teens and adults as the new mRNA jabs. That puts Novavax on more of a level playing field with Pfizer and Moderna this fall, even as a late entrant to the game.
The label for Novavax’s last Covid booster was far more restrictive. Last year, the FDA authorized it as a first booster dose for people ages 18 and older who couldn’t receive a new mRNA shot for accessibility or clinical reasons. That “basically disqualified a lot of people” from getting it last fall, according to Mamtani.
“Finally, after three years, Novavax has a label that puts its vaccine at parity with the mRNA shots,” Mamtani said. “I think the most powerful words on that label was that people can get it regardless of their previous Covid vaccination history.”
Logistical issues slowed down Pfizer, Moderna
Novavax’s vaccine is entering the market after Pfizer and Moderna had a bumpy start to the rollout of their shots. Insurance and supply-related issues left many Americans unable to find or access the new mRNA vaccines for free, which may give Novavax an opportunity to catch up and get more people to take its shot.
“We know that a lot of people have tried to get an mRNA vaccine, but they aren’t able to because of logistical challenges of access and distribution,” Jefferies analyst Roger Song told CNBC. “So, that’s one reason why the two or three weeks delay won’t necessarily be a hurdle for Novavax.”
There’s no way of knowing whether the rollout of Novavax’s new shot will see similar logistical snags or if it will have a smoother launch. The federal government shifted Covid vaccine distribution and coverage to the private market for the first time this fall. That has proved to be a tricky transition for the U.S. health-care system.
However, health-care providers and pharmacies have signaled that they are ironing out logistical issues and will be better equipped to handle them in the future.
Last week, a group of insurers told the Biden administration they were “largely, if not completely,” done with fixing delays in insurance coverage for the new Covid shots. Those delays had resulted in some patients getting charged up to $190 for a shot at pharmacies.
“Should further issues arise, we stand ready to swiftly implement system improvements,” the insurers said in a letter.
Some pharmacies, like Walgreens
, also appear to be resolving supply disruptions, which left many stores without any new Covid shots for patients to receive.
Covid vaccinations could peak later this fall
What’s more, Novavax’s new shot might actually be arriving at just the right time: a month before Covid vaccine demand is expected to peak in the U.S. this fall and winter.
Jefferies’ Song said the peak could follow a similar pattern as last season when most Covid boosters were administered in November. That’s partly because there is “less urgency” among Americans when it comes to Covid shots compared to early on in the pandemic, which could cause them to get vaccinated later rather than earlier.
“During the first season of Covid, everyone rushed to get vaccinations because it was really an emergency state. But now people have a mindset where they’re saying, ‘OK, I will wait and see how bad Covid really gets,’” Song said.
By November, Novavax’s new shot will likely be as widely available as shots from Pfizer and Moderna at pharmacies, doctor’s offices and other vaccine distribution sites.
But the biggest uncertainty this fall for all three companies is how many Americans will decide to get another Covid vaccine, Song said.
Last year’s uptake was already feeble: Only about 17% of the U.S. population — around 56 million people — received last year’s boosters, according to the Centers for Disease Control and Prevention.
“We don’t know how big the overall pie will be because we’ve never been in a commercial market for Covid vaccines,” he told CNBC. “This fall will set a new benchmark for the entire Covid vaccine space.”
Source: https://www.cnbc.com/2023/10/07/novavax-covid-vaccine-can-still-catch-up-to-pfizer-moderna-shots.html
TMF: This Could be Novavax's Big Opportunity
The Motley Fool
October 7, 2023
Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the lion's share of the market and revenue, and Novavax couldn't catch up.
As we head into a new vaccination season, Moderna and Pfizer once again reached commercialization first with their updated coronavirus vaccines. But this time, Novavax is only a few weeks behind -- and may have a better chance of gaining market share. In fact, this could be Novavax's big opportunity to prove its value in the world of coronavirus prevention -- and a key step to recurring vaccine revenue.
Updated coronavirus vaccines
Moderna and Pfizer scored a nod from the U.S. Food and Drug Administration for their updated vaccines in early September, and just this week Novavax earned an OK from the agency. So Moderna and Pfizer were able to start vaccinating about three weeks ahead of the smaller biotech company.
But Novavax may have more of a chance to gain market share now than it did in the first round of vaccinations. That's because the entire vaccine landscape is changing. Today, companies aren't just selling doses to governments. Instead, they are shifting to a commercial model, which involves selling doses directly to healthcare providers.
For vaccine makers, serving a greater number of clients in many more locations has slowed down the logistics of getting doses to their destinations. As a result, demand has surpassed supply in certain areas, and some pharmacies are even prioritizing the most at-risk people first.
So far, about 2 million Americans have received updated coronavirus shots, CNBC reported, and about half of Americans are interested in getting a shot, a Reuters poll shows. This means Novavax clearly could carve out market share if it is able to rapidly deliver promised doses to customers.
I wouldn't expect Novavax to sell nearly as many as leaders Pfizer and Moderna, since these players launched their updated vaccines first and sell dominant brands that healthcare providers have widely used in the past. But that's OK. This still could be Novavax's big opportunity to progressively establish itself.
The path to recurring revenue
Now here's why this is important. We're no longer talking about selling a vaccine once in a pandemic situation. The coronavirus is here to stay, health experts say, and that means vaccine makers could sell vaccines annually -- much like they do for the flu. And that equals recurring revenue, a very positive addition to any company's earnings picture.
What's more, a greater presence in the vaccine marketplace now may help Novavax excel later with a potential combined flu/coronavirus vaccine product.
Novavax, Moderna, and Pfizer all are working on combined candidates, but if the coronavirus vaccine market indeed mimics that of the flu, demand for such a product could be high -- and enough for all three companies to generate significant revenue annually.
What does all of this mean for investors? Well, it's important to keep an eye on Novavax's progress this vaccine season to see if it's able to make gains in the market and ensure deliveries to customers. If you're a cautious investor, Novavax still shouldn't move from your watch list to your buy list until we have more visibility on these points.
But if you're an aggressive investor, you may want to take the chance that the second time will be the charm for Novavax and scoop up a few shares. It's unlikely this biotech company will come close to the sales levels of its bigger rivals, but it still could reap long-term rewards from its vaccine innovation in the coronavirus and flu markets. And, if that happens, investors who get in early on the shares may win big.
Source: https://www.nasdaq.com/articles/this-could-be-novavaxs-big-opportunity
Todos Share Update - 10/6/23
No shares issued since update on 9/29/23.
https://www.otcmarkets.com/stock/TOMDF/security
Looks like baby girl was trying to convert dad's CD collection of Engelbert Humperdinck albums to cash to buy drugs. (page 25)
Now I better understand dad's infatuation with Gerald and the non-stop posting of the GC photo collection on this board. I'm sure GC was in dad's thoughts every time this song played. Should we start a GoFundMe to replace dad's Engelbert CD collection? Would have to purchase the CDs directly and send to dad. If given the money directly, he might flitter it away in a penny stock like MONI with no products, no revenue and no employees.
Can't Take My Eyes Off Of You - Engelbert Humperdinck
The new Novavax vaccine received FDA approval today. Price jumped 18% immediately on the news. Huge EU orders already lined up awaiting EU approval. Spent the last few weeks loading up on NVAX shares as this has been the most shorted stock on Wall Street for a month. Large, possibly extreme short squeeze coming. Novavax is the only vaccine recommended by GC. I'm getting it as soon as it's available.
I have invested in this company (Bioxytran) as well as in Todos.
Bill approved for temporary government funding should keep FDA open long enough to approve Novavax vaccine. Short squeeze back on the table.
Create a temporary email address to use. I don't care. And I can only remember ever emailing JP once or twice, so I'm not sure what personal harassment you are referring to. Have your buddy JP post some of the harassing emails I sent.
Yes, I do really think you are that stupid, based on the claims you have made here with zero proof.
How does one come to the conclusion that I have many aliases just because I'm not willing to have a PM with you? Talk about spouting BS on a public board. With your logic, anyone can post anything and use the convenient "it was posted but got deleted" excuse. Sorry, but that's not proof. About as valid as claims lottery winners have to deal with from "friends" who claimed they made a verbal agreement to share their winnings if they ever won, and are now bringing lawsuits trying to prove that, with no proof other than hearsay.
Provide your email address via PM and we can carry on this discussion via email.
I make plenty of money and could buy 100 IHUB memberships. But it's not worth even the price of one membership to PM some clown who makes such unsubstantiated claims, especially when the person the claim is about has posted saying it's a lie. Memory is a tricky thing. That's why people ask for proof of claims from the past. People don't always remember the facts correctly. It's not that they're intentionally lying, but memories change over time. That's been proven in many studies.
So here's another angle... in reviewing posts here I also came across one I had forgotten about, where you claimed I was Warp. So if I am Warp in your mind, I'm telling you here and now I NEVER attended any investor conference. Provide proof otherwise, or STFU about it. You're making a fool of yourself with every post making this claim.
I call BS on your claim you had a picture of Warp. Around the time this claim was made here back in late June, I remember Warp posting about it on another TOMDF board I was also following. I dug it up and here is the post.
I'm guessing what you refer to was a photo someone who attended the conference posted, and the sleuths on the AMBS board were trying to identify what posters attended. But when a person makes a post they have never attended any meetings associated with the company, I tend to believe them over what some random person claims who believes he has connected the dots. So I think your claim is crap, just as I think JP's claim that I am Warp (or Maui, or Redspeed, or any number of other posters) is crap. Yours and JP's methodology in connecting the dots and making bogus claims is pathetically off track.
And if you'd ever bothered to check my profile, you'd see I'm not a paying IHUB member, so I cannot send you a PM, except during happy hour on Fridays.